Information  X 
Enter a valid email address

Oxford Biomedica PLC (OXB)

  Print      Mail a friend       Annual reports

Thursday 20 January, 2011

Oxford Biomedica PLC

Notice of Preliminary Results

RNS Number : 7767Z
Oxford Biomedica PLC
20 January 2011
 

 

OXFORD BIOMEDICA: NOTICE OF PRELIMINARY RESULTS

RESULTS DATE: 2 MARCH 2011

 

Oxford, UK - 20 January 2011: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), today announces that it will be releasing its preliminary results for the twelve months ended 31 December 2010 on Wednesday 2 March 2011.

 

An analyst briefing will be held at 9:30am GMT on Wednesday 2 March 2011 at the offices of M:Communications, CityPoint, 1 Ropemaker Street, London, EC2Y 9AW.

 

Simultaneously to the analyst briefing at 9:30am GMT, there will be a live audio webcast of the presentation.  To connect to the webcast facility, please visit the Company's website: www.oxfordbiomedica.co.uk approximately 10 minutes (9:20am GMT) before the start of the briefing.  A replay will be made available shortly after the presentation.

 

-Ends-

 

For further information, please contact:


Oxford BioMedica plc:

Lara Mott, Head of Corporate Communications

 

Tel: +44 (0)1865 783 000

 

Media/Financial Enquiries:

Emma Thompson/Amber Bielecka/Rob Newman

M:Communications

 

Tel: +44 (0)20 7920 2342

 

 

US Enquiries:

Simon Harnest

The Trout Group LLC

 

Tel: +1 (646) 378 2900

 

Notes to editors

1. Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Pfizer.  Further information is available at www.oxfordbiomedica.co.uk.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NOREAPFNFELFEFF